Newcastle disease viruses and uses thereof

US12042534B2 · kind B2 · utility

Assignees

• ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · US
• Memorial Sloan Kettering Cancer Center · US

Inventors

• Peter Palese · Leonia, US
• Adolfo Garcia-Sastre · New York, US
• Dmitriy Zamarin · New York, US
• Jedd D. Wolchok · New York, US

Key dates

• Filing date: May 11, 2018
• Grant date: Jul 23, 2024
• Expiry date: Dec 4, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18143
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 (“PD-1”) or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.